Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Verified Perscriptions System ETCR -- Ignore unavailable to you. Want to Upgrade?

To: DaiTN who wrote (340)	8/6/2002 2:36:20 PM
From: uthabros	Respond to of 397

Let me try to clarify by giving you exerpts from the letter I recieved from the transfer agent. 1) Preferred shares were computed by the issuer as being 90% of the co.'s average 20 day market price beginning 20 trading days prior to the conversion date of July 16,2002. The company's average market price within this period, as been determined by the issuer, was .08 and therefore the conversion ratio is .07. 2) Inasmuch as the holding period for the Class A Common Shares is deemed to have begun on July 16,2001,any shareholder desiring to have the restrictions lifted may do so in the manner described in Rule 144, through the shareholder's broker. The company deserves the right to process all such requests until Dec. 1, 2002 and thereafter, at which time ot rimes the restrictions will be removed pursuant to rule 144. I'm not sure where the co.'s lawyer came in but maybe I was hittin the Apple pipe at that time! ;>)))!!!

To: DaiTN who wrote (340)	8/6/2002 2:41:19 PM
From: uthabros	Read Replies (1) \| Respond to of 397

The co. Pres. speaks again. 2 days in a row. That's a record. Sounds good though. LEXINGTON, Ky., Aug 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- Equity Technologies & Resources, Inc. (OTC Bulletin Board: ETCR) President, Frank Dickey, said today that a year long investigation of prescription drug diversion schemes, in six states, would not take nearly so long if the patent-pending Verified Prescriptions Safeguards(TM) real time monitoring system was being utilized. "We have the system capability to monitor prescription drug diversion," emphasized Dickey, "protect ethical, lawful physicians, pharmacists, and patients, alert regulators to potential criminal activity and save the taxpayers millions of dollars." More than a dozen Federal agencies and scores of state and local law enforcement officials have been conducting the investigation for more than a year in Kentucky, Maine, North and South Carolina, Tennessee, and Virginia. An investigation of two Northern Virginia physicians indicates patients may be fraudulently obtaining painkillers from as far away as California, Oregon and Louisiana. "By monitoring scheduled prescriptions, in real time with the VPS(TM) system, fraudulent and abusive patterns would be instantly identified. This will enable our law enforcement resources to be utilized much more efficiently," Dickey added. "Use of the VPS(TM) system would have detected this activity and information with the stroke of a finger," Dickey said. "The doctors and pharmacists would have known, and the regulator would have received this information in real time, allowing for swift, appropriate action if illegal activity was involved." This press release contains forward-looking statements that reflect the Company's current expectations regarding future events. While these statements reflect the Company's best current judgment, they are subject to risks and uncertainties. Actual results may differ significantly from projected results due to a number of factors, including, but not limited to assumptions beliefs and opinions relating to the business and growth strategy of Equity Technologies & Resources, Inc. and it's wholly owned subsidiary Verified Prescription Safeguards, Inc., and implementation thereof, based upon the Company's interpretation and analysis of financial and market conditions, the decisions of businesses with whom the Company is either engaged in business with or negotiating, healthcare industry trends and management's ability to successfully finance, develop, market, sell and implement its e- commerce and internet solutions, clinical and financial e-transaction services and software applications to physicians, pharmacies, governmental agencies, laboratories, insurance companies, HMO's, and payers. These factors and other risk factors are more fully discussed in the Company's filings with the Securities and Exchange Commission. The Company expressly disclaims any intent or obligation to update any forward-looking statements.